| Document Date: 2013-07-12 14:26:37
Open Document File Size: 72,36 KBShare Result on Facebook
Company GlaxoSmithKline Inc. / FOREWORD Health Canada / Manufacturer/Sponsor GlaxoSmithKline Inc. / Health Canada GlaxoSmithKline Inc. / / Country Canada / / Event FDA Phase / / IndustryTerm proposed manufacturing sites / pharmaceutical development / manufacturing activities / particular product / manufacturing / nervous systems / degradation products / drug product / manufacturing process / food / / MedicalCondition lung eosinophilia model / skin inflammation / delayed type hypersensitivity / seasonal allergic rhinitis / hypersensitivity / inflammation / rhinitis / ear inflammation / lung eosinophilia / / Organization Health Products and Food Branch / / Position General Information Fluticasone furoate / / Product fluticasone propionate / disodium edetate / Avamys / SBD / / PublishedMedium the Health Canada review / / Technology Pharmacokinetics / Pharmacodynamics / /
SocialTag |
Summary Basis of Decision Avamys